Top Markets
Coin of the day
OncoVista Innovative Therapies, Inc. OncoVista Innovative Therapies, Inc.

OncoVista Innovative Therapies, Inc.

OVIT
Rank in Stocks #42301
OncoVista Innovative Therapies, Inc. does not have significant business.... OncoVista Innovative Therapies, Inc. does not have significant business. Previously, it engaged in development of targeted anticancer therapies by utilizing tumor-associated biomarkers. The company was founded in 2004 and is based in San Antonio, Texas.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$2.36K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade OncoVista Innovative Therapies, Inc. (OVIT)

Category

P/E ratio for OncoVista Innovative Therapies, Inc. (OVIT)
P/E ratio as of 2026 TTM: 0
According to OncoVista Innovative Therapies, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for OncoVista Innovative Therapies, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
28.05 -
US
31.14 -
NL
- -
CH
19.30 -
BE
- -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.